(Total Views: 361)
Posted On: 02/04/2022 7:50:31 AM
Post# of 17
WILL RESMETIROM PROVE TO BE A GAMECHANGER IN NASH?
$MDGL
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) a clinical-stage biopharmaceutical company, announced positive topline results from a Phase III trial evaluating its lead candidate Resmetirom (MGL-3196), in non-alcoholic fatty liver disease (NAFLD).
The Positive Data is the first step towards its goal of becoming a potential game changer in NASH, as a lot rides on the data from the Phase 3 data from its NASH trial , which is expected later this year.
Read on to find out more !
https://www.aviseanalytics.com/will-resmetiro...r-in-nash/
$MDGL
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) a clinical-stage biopharmaceutical company, announced positive topline results from a Phase III trial evaluating its lead candidate Resmetirom (MGL-3196), in non-alcoholic fatty liver disease (NAFLD).
The Positive Data is the first step towards its goal of becoming a potential game changer in NASH, as a lot rides on the data from the Phase 3 data from its NASH trial , which is expected later this year.
Read on to find out more !
https://www.aviseanalytics.com/will-resmetiro...r-in-nash/
(0)
(0)
